EUVIMEDEUVIMED entdecken
Crossref

Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [ 68 Ga]Ga-FAPI-FUSCC-II

Xinyue Du, Bingxin Gu, Xiao Wang, Xiangwei Wang, Mengjing Ji, Jianping Zhang, Simin He, Xiaoping Xu, Zhongyi Yang iD, Shaoli Song iD

Molecular Pharmaceutics · 05.02.2024 · 21 (2) · 904-915

DOI: 10.1021/acs.molpharmaceut.3c01008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 05.01.2024. Verfasst von Xinyue Du und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, P. R. China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Anti-Cancer Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibroblast activation protein (FAP), a type II integral membrane serine protease, is a promising target for tumor diagnosis and therapy. OncoFAP has been recently discovered for PET imaging procedures for various solid malignancies. In this study, we presented the development of manual radiolabeling procedures for the preparation of OncoFAP-based radiopharmaceuticals for cancer imaging. A novel series of [68Ga/177Lu]Ga/Lu-FAPI-FUSCC-I/II were produced with high radiochemical yields. [68Ga]Ga-FAPI-FUSCC-I/II and [177Lu]Lu-FAPI-FUSCC-I/II were stable in phosphate-buffered saline, fetal bovine serum, and human serum for at least 3 h. In vitro cellular uptake and blocking experiments implied that they had specificity to FAP. Additionally, the low nanomolar IC50 values of FAPI-FUSCC-II indicated that it had a high target affinity to FAP. The in vivo biodistribution and blocking study in mice bearing HT-1080-FAP tumors showed that both exhibited specific tumor uptake. [68Ga]Ga-FAPI-FUSCC-II showed a higher tumor uptake and a higher tumor/nontarget ratio than [68Ga]Ga-FAPI-FUSCC-I and [68Ga]Ga-FAPI-04. The results of ex vivo biodistribution were in accordance with the biodistribution results. Clinical [68Ga]Ga-FAPI-FUSCC-II-PET/CT imaging further demonstrated its favorable biodistribution and kinetics with elevated and reliable uptake by primary tumors (maximum standardized uptake value (SUVmax), 12.17 ± 6.67) and distant metastases (SUVmax, 9.24 ± 4.28). In summary, [68Ga]Ga-FAPI-FUSCC-II displayed increased tumor uptake and retention compared to [68Ga]Ga-FAPI-04, giving it potential as a promising tracer for the diagnostic imaging of malignant tumors with positive FAP expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyNeoplasmsHumansAnimalsMiceGallium RadioisotopesTissue DistributionPositron-Emission TomographyRadiopharmaceuticals

Stichwörter der Autor:innen

cancer-associated fibroblastsfibroblast activation proteinpositron emission tomographyradiolabeling

Substanzen

Gallium RadioisotopesRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, P. R. China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P. R. China.
  • Center for Biomedical Imaging, Fudan University, Shanghai 200032, P. R. China.
  • Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai 200032, P. R. China.
  • College of Chemistry and Materials Science, Shanghai Normal University, Shanghai 200233, P. R. China.

ORCID-Profile: Zhongyi Yang, Shaoli Song

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Shanghai Anti-Cancer Association
  • Special Clinical Research Project of Health Industry of Shanghai Municipal Health Commission

Zitieren

APA

Du, X., Gu, B., Wang, X., Wang, X., Ji, M., Zhang, J., He, S., Xu, X., Yang, Z., & Song, S. (2024). Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [ 68 Ga]Ga-FAPI-FUSCC-II. Molecular Pharmaceutics, 21(2), 904-915. https://doi.org/10.1021/acs.molpharmaceut.3c01008

Vancouver

Du X, Gu B, Wang X, Wang X, Ji M, Zhang J, et al. Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [ 68 Ga]Ga-FAPI-FUSCC-II. Molecular Pharmaceutics. 2024;21(2):904-915. doi:10.1021/acs.molpharmaceut.3c01008

BibTeX
@article{Du2024,
  author = {Du, Xinyue and Gu, Bingxin and Wang, Xiao and Wang, Xiangwei and Ji, Mengjing and Zhang, Jianping and He, Simin and Xu, Xiaoping and Yang, Zhongyi and Song, Shaoli},
  title = {Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [ 68 Ga]Ga-FAPI-FUSCC-II},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  volume = {21},
  number = {2},
  pages = {904--915},
  doi = {10.1021/acs.molpharmaceut.3c01008}
}
Kostenlos starten →